Exhibit 10.1
UST Sequence Number: 16
UNITED STATES DEPARTMENT OF THE TREASURY
1500 PENNSYLVANIA AVENUE, NW
WASHINGTON, D.C. 20220
Dear Ladies and Gentlemen:
The company set forth on the
signature page hereto (the “ Company ”)
intends to issue in a private placement the number of shares of a
series of its preferred stock set forth on Schedule A hereto (the
“ Preferred Shares ”) and a warrant to purchase
the number of shares of its common stock set forth on Schedule A
hereto (the “ Warrant ” and, together with the
Preferred Shares, the “ Purchased Securities ”)
and the United States Department of the Treasury (the “
Investor ”) intends to purchase from the Company the
Purchased Securities.
The purpose of this letter agreement
is to confirm the terms and conditions of the purchase by the
Investor of the Purchased Securities. Except to the extent
supplemented or superseded by the terms set forth herein or in the
Schedules hereto, the provisions contained in the Securities
Purchase Agreement – Standard Terms attached hereto as
Exhibit A (the “ Securities Purchase Agreement
”) are incorporated by reference herein. Terms that are
defined in the Securities Purchase Agreement are used in this
letter agreement as so defined. In the event of any
inconsistency between this letter agreement and the Securities
Purchase Agreement, the terms of this letter agreement shall
govern.
Each of the Company and the Investor
hereby confirms its agreement with the other party with respect to
the issuance by the Company of the Purchased Securities and the
purchase by the Investor of the Purchased Securities pursuant to
this letter agreement and the Securities Purchase Agreement on the
terms specified on Schedule A hereto.
This letter agreement (including the
Schedules hereto) and the Securities Purchase Agreement (including
the Annexes thereto) and the Warrant constitute the entire
agreement, and supersede all other prior agreements,
understandings, representations and warranties, both written and
oral, between the parties, with respect to the subject matter
hereof. This letter agreement constitutes the “Letter
Agreement” referred to in the Securities Purchase
Agreement.
This letter agreement may be
executed in any number of separate counterparts, each such
counterpart being deemed to be an original instrument, and all such
counterparts will together constitute the same agreement.
Executed signature pages to this letter agreement may be
delivered by facsimile and such facsimiles will be deemed as
sufficient as if actual signature pages had been
delivered.
* * *
In witness whereof, this letter
agreement has been duly executed and delivered by the duly
authorized representatives of the parties hereto as of the date
written below.
|
|
UNITED STATES DEPARTMENT OF THE
TREASURY
|
|
|
|
|
|
|
|
|
By:
|
/s/ Neel Kashkari
|
|
|
|
Name:
|
Neel Kashkari
|
|
|
|
Title:
|
Interim Assistant Secretary for
Financial
|
|
|
|
|
|
Stability
|
|
|
|
|
|
|
|
|
|
|
COMPANY: COMERICA INCORPORATED
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Jon W. Bilstrom
|
|
|
|
Name:
|
Jon W. Bilstrom
|
|
|
|
Title:
|
Executive Vice President – Governance,
Regulatory Relations and Legal Affairs
|
Date: November 14, 2008
Exhibit A
SECURITIES PURCHASE
AGREEMENT
EXHIBIT A
SECURITIES PURCHASE
AGREEMENT
STANDARD TERMS
TABLE OF CONTENTS
|
|
|
Page
|
|
|
|
|
|
|
Article I
|
|
|
|
|
|
|
|
Purchase; Closing
|
|
|
|
|
|
|
1.1
|
Purchase
|
1
|
|
1.2
|
Closing
|
2
|
|
1.3
|
Interpretation
|
4
|
|
|
|
|
|
|
Article II
|
|
|
|
|
|
|
|
Representations and Warranties
|
|
|
|
|
|
|
2.1
|
Disclosure
|
4
|
|
2.2
|
Representations and Warranties of the
Company
|
5
|
|
|
|
|
|
|
Article III
|
|
|
|
|
|
|
|
Covenants
|
|
|
|
|
|
|
3.1
|
Commercially Reasonable Efforts
|
13
|
|
3.2
|
Expenses
|
14
|
|
3.3
|
Sufficiency of Authorized Common Stock; Exchange
Listing
|
14
|
|
3.4
|
Certain Notifications Until Closing
|
15
|
|
3.5
|
Access, Information and
Confidentiality
|
15
|
|
|
|
|
|
|
Article IV
|
|
|
|
|
|
|
|
Additional Agreements
|
|
|
|
|
|
|
4.1
|
Purchase for Investment
|
16
|
|
4.2
|
Legends
|
16
|
|
4.3
|
Certain Transactions
|
18
|
|
4.4
|
Transfer of Purchased Securities and Warrant
Shares; Restrictions on Exercise of the Warrant
|
18
|
|
4.5
|
Registration Rights.
|
19
|
|
4.6
|
Voting of Warrant Shares
|
30
|
|
4.7
|
Depositary Shares
|
31
|
|
4.8
|
Restriction on Dividends and
Repurchases
|
31
|
|
4.9
|
Repurchase of Investor Securities
|
32
|
|
4.10
|
Executive Compensation
|
33
|
-i-
|
|
Article V
|
|
|
|
|
|
|
|
Miscellaneous
|
|
|
5.1
|
Termination
|
34
|
|
5.2
|
Survival of Representations and
Warranties
|
34
|
|
5.3
|
Amendment
|
34
|
|
5.4
|
Waiver of Conditions
|
34
|
|
5.5
|
Governing Law: Submission to Jurisdiction,
Etc.
|
35
|
|
5.6
|
Notices
|
35
|
|
5.7
|
Definitions
|
35
|
|
5.8
|
Assignment
|
36
|
|
5.9
|
Severability
|
36
|
|
5.10
|
No Third Party Beneficiaries
|
36
|
-ii-
LIST OF ANNEXES
|
ANNEX A:
|
|
FORM OF CERTIFICATE OF DESIGNATIONS FOR
PREFERRED STOCK
|
|
|
|
|
|
ANNEX B:
|
|
FORM OF WAIVER
|
|
|
|
|
|
ANNEX C:
|
|
FORM OF OPINION
|
|
|
|
|
|
ANNEX D:
|
|
FORM OF WARRANT
|
-iii-
INDEX OF DEFINED TERMS
|
Term
|
|
Location of
Definition
|
|
|
Affiliate
|
|
5.7(b)
|
|
|
Agreement
|
|
Recitals
|
|
|
Appraisal Procedure
|
|
4.9(c)(i)
|
|
|
Appropriate Federal Banking
Agency
|
|
2.2(s)
|
|
|
Bankruptcy Exceptions
|
|
2.2(d)
|
|
|
Benefit Plans
|
|
1.2(d)(iv)
|
|
|
Board of Directors
|
|
2.2(f)
|
|
|
Business Combination
|
|
4.4
|
|
|
business day
|
|
1.3
|
|
|
Capitalization Date
|
|
2.2(b)
|
|
|
Certificate of
Designations
|
|
1.2(d)(iii)
|
|
|
Charter
|
|
1.2(d)(iii)
|
|
|
Closing
|
|
1.2(a)
|
|
|
Closing Date
|
|
1.2(a)
|
|
|
Code
|
|
2.2(n)
|
|
|
Common Stock
|
|
Recitals
|
|
|
Company
|
|
Recitals
|
|
|
Company Financial
Statements
|
|
2.2(h)
|
|
|
Company Material Adverse
Effect
|
|
2.1(a)
|
|
|
Company Reports
|
|
2.2(i)(i)
|
|
|
Company Subsidiary; Company
Subsidiaries
|
|
2.2(i)(i)
|
|
|
control; controlled by; under common
control with
|
|
5.7(b)
|
|
|
Controlled Group
|
|
2.2(n)
|
|
|
CPP
|
|
Recitals
|
|
|
EESA
|
|
1.2(d)(iv)
|
|
|
ERISA
|
|
2.2(n)
|
|
|
Exchange Act
|
|
2.1(b)
|
|
|
Fair Market Value
|
|
4.9(c)(ii)
|
|
|
GAAP
|
|
2.1(a)
|
|
|
Governmental Entities
|
|
1.2(c)
|
|
|
Holder
|
|
4.5(k)(i)
|
|
|
Holders’ Counsel
|
|
4.5(k)(ii)
|
|
|
Indemnitee
|
|
4.5(g)(i)
|
|
|
Information
|
|
3.5(b)
|
|
|
Initial Warrant Shares
|
|
Recitals
|
|
|
Investor
|
|
Recitals
|
|
|
Junior Stock
|
|
4.8(c)
|
|
|
knowledge of the Company;
Company’s knowledge
|
|
5.7(c)
|
|
|
Last Fiscal Year
|
|
2.1(b)
|
|
|
Letter Agreement
|
|
Recitals
|
|
|
officers
|
|
5.7(c)
|
|
-iv-
|
Term
|
|
Location of
Definition
|
|
|
Parity Stock
|
|
4.8(c)
|
|
|
Pending Underwritten Offering
|
|
4.5(l)
|
|
|
Permitted Repurchases
|
|
4.8(a)(ii)
|
|
|
Piggyback Registration
|
|
4.5(a)(iv)
|
|
|
Plan
|
|
2.2(n)
|
|
|
Preferred Shares
|
|
Recitals
|
|
|
Preferred Stock
|
|
Recitals
|
|
|
Previously Disclosed
|
|
2.1(b)
|
|
|
Proprietary Rights
|
|
2.2(u)
|
|
|
Purchase
|
|
Recitals
|
|
|
Purchase Price
|
|
1.1
|
|
|
Purchased Securities
|
|
Recitals
|
|
|
Qualified Equity Offering
|
|
4.4
|
|
|
register; registered; registration
|
|
4.5(k)(iii)
|
|
|
Registrable Securities
|
|
4.5(k)(iv)
|
|
|
Registration Expenses
|
|
4.5(k)(v)
|
|
|
Regulatory Agreement
|
|
2.2(s)
|
|
|
Rule 144; Rule 144A; Rule 159A;
Rule 405; Rule 415
|
|
4.5(k)(vi)
|
|
|
Schedules
|
|
Recitals
|
|
|
SEC
|
|
2.1(b)
|
|
|
Securities Act
|
|
2.2(a)
|
|
|
Selling Expenses
|
|
4.5(k)(vii)
|
|
|
Senior Executive Officers
|
|
4.10
|
|
|
Share Dilution Amount
|
|
4.8(a)(ii)
|
|
|
Shelf Registration Statement
|
|
4.5(a)(ii)
|
|
|
Signing Date
|
|
2.1(a)
|
|
|
Special Registration
|
|
4.5(i)
|
|
|
Stockholder Proposals
|
|
3.1(b)
|
|
|
subsidiary
|
|
5.8(a)
|
|
|
Tax; Taxes
|
|
2.2(o)
|
|
|
Transfer
|
|
4.4
|
|
|
Warrant
|
|
Recitals
|
|
|
Warrant Shares
|
|
2.2(d)
|
|
-v-
SECURITIES PURCHASE AGREEMENT
– STANDARD TERMS
Recitals:
WHEREAS, the United States
Department of the Treasury (the “ Investor ”)
may from time to time agree to purchase shares of preferred stock
and warrants from eligible financial institutions which elect to
participate in the Troubled Asset Relief Program Capital Purchase
Program (“ CPP ”);
WHEREAS, an eligible financial
institution electing to participate in the CPP and issue securities
to the Investor (referred to herein as the “ Company
”) shall enter into a letter agreement (the “ Letter
Agreement ”) with the Investor which incorporates this
Securities Purchase Agreement – Standard Terms;
WHEREAS, the Company agrees to
expand the flow of credit to U.S. consumers and businesses on
competitive terms to promote the sustained growth and vitality of
the U.S. economy;
WHEREAS, the Company agrees to work
diligently, under existing programs, to modify the terms of
residential mortgages as appropriate to strengthen the health of
the U.S. housing market;
WHEREAS, the Company intends to
issue in a private placement the number of shares of the series of
its Preferred Stock (“ Preferred Stock ”) set
forth on Schedule A to the Letter Agreement (the “
Preferred Shares ”) and a warrant to purchase the
number of shares of its Common Stock (“ Common Stock
”) set forth on Schedule A to the Letter Agreement
(the “ Initial Warrant Shares ”) (the “
Warrant ” and, together with the Preferred Shares, the
“ Purchased Securities ”) and the Investor
intends to purchase (the “ Purchase ”) from the
Company the Purchased Securities; and
WHEREAS, the Purchase will be
governed by this Securities Purchase Agreement – Standard
Terms and the Letter Agreement, including the schedules thereto
(the “ Schedules ”), specifying additional terms
of the Purchase. This Securities Purchase Agreement –
Standard Terms (including the Annexes hereto) and the Letter
Agreement (including the Schedules thereto) are together referred
to as this “Agreement”. All references in this
Securities Purchase Agreement – Standard Terms to
“Schedules” are to the Schedules attached to the Letter
Agreement.
NOW, THEREFORE
, in consideration of the premises,
and of the representations, warranties, covenants and agreements
set forth herein, the parties agree as follows:
Article I
Purchase; Closing
1.1
Purchase . On the terms and subject to the conditions set
forth in this Agreement, the Company agrees to sell to the
Investor, and the Investor agrees to purchase from the Company, at
the Closing (as hereinafter defined), the Purchased Securities for
the price set forth on Schedule A (the “ Purchase
Price ”).
1.2
Closing .
(a)
On the terms and subject to the
conditions set forth in this Agreement, the closing of the Purchase
(the “ Closing ”) will take place at the
location specified in Schedule A , at the time and on the
date set forth in Schedule A or as soon as practicable
thereafter, or at such other place, time and date as shall be
agreed between the Company and the Investor. The time and date on
which the Closing occurs is referred to in this Agreement as the
“ Closing Date ”.
(b)
Subject to the fulfillment or waiver
of the conditions to the Closing in this Section 1.2, at the
Closing the Company will deliver the Preferred Shares and the
Warrant, in each case as evidenced by one or more certificates
dated the Closing Date and bearing appropriate legends as
hereinafter provided for, in exchange for payment in full of the
Purchase Price by wire transfer of immediately available United
States funds to a bank account designated by the Company on
Schedule A.
(c)
The respective obligations of each
of the Investor and the Company to consummate the Purchase are
subject to the fulfillment (or waiver by the Investor and the
Company, as applicable) prior to the Closing of the conditions that
(i) any approvals or authorizations of all United States and
other governmental, regulatory or judicial authorities
(collectively, “ Governmental Entities ”)
required for the consummation of the Purchase shall have been
obtained or made in form and substance reasonably satisfactory to
each party and shall be in full force and effect and all waiting
periods required by United States and other applicable law, if any,
shall have expired and (ii) no provision of any applicable
United States or other law and no judgment, injunction, order or
decree of any Governmental Entity shall prohibit the purchase and
sale of the Purchased Securities as contemplated by this
Agreement.
(d)
The obligation of the Investor to
consummate the Purchase is also subject to the fulfillment (or
waiver by the Investor) at or prior to the Closing of each of the
following conditions:
(i)
(A) the representations and
warranties of the Company set forth in
(x) Section 2.2(g) of this Agreement shall be true
and correct in all respects as though made on and as of the Closing
Date, (y) Sections 2.2(a) through (f) shall be true
and correct in all material respects as though made on and as of
the Closing Date (other than representations and warranties that by
their terms speak as of another date, which representations and
warranties shall be true and correct in all material respects as of
such other date) and (z) Sections 2.2(h) through
(v) (disregarding all qualifications or limitations set forth
in such representations and warranties as to
“materiality”, “Company Material Adverse
Effect” and words of similar import) shall be true and
correct as though made on and as of the Closing Date (other than
representations and warranties that by their terms speak as of
another date, which representations and warranties shall be true
and correct as of such other date), except to the extent that the
failure of such representations and warranties referred to in this
Section 1.2(d)(i)(A)(z) to be so true and correct,
individually or in the aggregate, does not have and would not
reasonably be expected to have a Company Material Adverse Effect
and (B) the Company shall have
-2-
performed in all material respects
all obligations required to be performed by it under this Agreement
at or prior to the Closing;
(ii)
the Investor shall have received a
certificate signed on behalf of the Company by a senior executive
officer certifying to the effect that the conditions set forth in
Section 1 .2(d)(i) have been satisfied;
(iii)
the Company shall have duly adopted
and filed with the Secretary of State of its jurisdiction of
organization or other applicable Governmental Entity the amendment
to its certificate or articles of incorporation, articles of
association, or similar organizational document (“
Charter ”) in substantially the form attached hereto
as Annex A (the “ Certificate of Designations
”) and such filing shall have been accepted;
(iv)
(A) the Company shall have
effected such changes to its compensation, bonus, incentive and
other benefit plans, arrangements and agreements (including golden
parachute, severance and employment agreements) (collectively,
“ Benefit Plans ”) with respect to its Senior
Executive Officers (and to the extent necessary for such changes to
be legally enforceable, each of its Senior Executive Officers shall
have duly consented in writing to such changes), as may be
necessary, during the period that the Investor owns any debt or
equity securities of the Company acquired pursuant to this
Agreement or the Warrant, in order to comply with
Section 111(b) of the Emergency Economic Stabilization
Act of 2008 (“ EESA ”) as implemented by
guidance or regulation thereunder that has been issued and is in
effect as of the Closing Date, and (B) the Investor shall have
received a certificate signed on behalf of the Company by a senior
executive officer certifying to the effect that the condition set
forth in Section 1.2(d)(iv)(A) has been satisfied;
(v)
each of the Company’s Senior
Executive Officers shall have delivered to the Investor a written
waiver in the form attached hereto as Annex B releasing the
Investor from any claims that such Senior Executive Officers may
otherwise have as a result of the issuance, on or prior to the
Closing Date, of any regulations which require the modification of,
and the agreement of the Company hereunder to modify, the terms of
any Benefit Plans with respect to its Senior Executive Officers to
eliminate any provisions of such Benefit Plans that would not be in
compliance with the requirements of Section 111(b) of the
EESA as implemented by guidance or regulation thereunder that has
been issued and is in effect as of the Closing Date;
(vi)
the Company shall have delivered to
the Investor a written opinion from counsel to the Company (which
may be internal counsel), addressed to the Investor and dated as of
the Closing Date, in substantially the form attached hereto as
Annex C ;
(vii)
the Company shall have delivered
certificates in proper form or, with the prior consent of the
Investor, evidence of shares in book-entry form, evidencing the
Preferred Shares to Investor or its designee(s); and
-3-
(viii)
the Company shall have duly executed
the Warrant in substantially the form attached hereto as
Annex D and delivered such executed Warrant to the
Investor or its designee(s).
1.3
Interpretation
. When a reference is made in this
Agreement to “Recitals,” “Articles,”
“Sections,” or “Annexes” such reference
shall be to a Recital, Article or Section of, or Annex
to, this Securities Purchase Agreement – Standard Terms, and
a reference to “Schedules” shall be to a Schedule to
the Letter Agreement, in each case, unless otherwise indicated. The
terms defined in the singular have a comparable meaning when used
in the plural, and vice versa. References to “herein”,
“hereof”, “hereunder” and the like refer to
this Agreement as a whole and not to any particular section or
provision, unless the context requires otherwise. The table of
contents and headings contained in this Agreement are for reference
purposes only and are not part of this Agreement. Whenever the
words “include,” “includes” or
“including” are used in this Agreement, they shall be
deemed followed by the words “without limitation.” No
rule of construction against the draftsperson shall be applied
in connection with the interpretation or enforcement of this
Agreement, as this Agreement is the product of negotiation between
sophisticated parties advised by counsel. All references to
“$” or “dollars” mean the lawful currency
of the United States of America. Except as expressly stated in this
Agreement, all references to any statute, rule or regulation
are to the statute, rule or regulation as amended, modified,
supplemented or replaced from time to time (and, in the case of
statutes, include any rules and regulations promulgated under
the statute) and to any section of any statute, rule or
regulation include any successor to the section. References to a
“ business day ” shall mean any day except
Saturday, Sunday and any day on which banking institutions in the
State of New York generally are authorized or required by law or
other governmental actions to close.
Article II
Representations and Warranties
2.1
Disclosure
.
(a)
“ Company Material Adverse
Effect ” means a material adverse effect on (i) the
business, results of operation or financial condition of the
Company and its consolidated subsidiaries taken as a whole;
provided , however , that Company Material Adverse
Effect shall not be deemed to include the effects of
(A) changes after the date of the Letter Agreement (the
“ Signing Date ”) in general business, economic
or market conditions (including changes generally in prevailing
interest rates, credit availability and liquidity, currency
exchange rates and price levels or trading volumes in the United
States or foreign securities or credit markets), or any outbreak or
escalation of hostilities, declared or undeclared acts of war or
terrorism, in each case generally affecting the industries in which
the Company and its subsidiaries operate, (B) changes or
proposed changes after the Signing Date in generally accepted
accounting principles in the United States (“ GAAP
”) or regulatory accounting requirements, or authoritative
interpretations thereof, (C) changes or proposed changes after
the Signing Date in securities, banking and other laws of general
applicability or related policies or interpretations of
Governmental Entities (in the case of each of these clauses (A),
(B) and (C), other than changes
-4-
or occurrences to the extent that such changes
or occurrences have or would reasonably be expected to have a
materially disproportionate adverse effect on the Company and its
consolidated subsidiaries taken as a whole relative to comparable
U.S. banking or financial services organizations), or
(D) changes in the market price or trading volume of the
Common Stock or any other equity, equity-related or debt securities
of the Company or its consolidated subsidiaries (it being
understood and agreed that the exception set forth in this clause
(D) does not apply to the underlying reason giving rise to or
contributing to any such change); or (ii) the ability of the
Company to consummate the Purchase and the other transactions
contemplated by this Agreement and the Warrant and perform its
obligations hereunder or thereunder on a timely basis.
(b)
“ Previously Disclosed
” means information set forth or incorporated in the
Company’s Annual Report on Form 10-K for the most
recently completed fiscal year of the Company filed with the
Securities and Exchange Commission (the “ SEC ”)
prior to the Signing Date (the “ Last Fiscal Year
”) or in its other reports and forms filed with or furnished
to the SEC under Sections 13(a), 14(a) or 15(d) of the
Securities Exchange Act of 1934 (the “ Exchange Act
”) on or after the last day of the Last Fiscal Year and prior
to the Signing Date.
2.2
Representations and Warranties of
the Company . Except as
Previously Disclosed, the Company represents and warrants to the
Investor that as of the Signing Date and as of the Closing Date (or
such other date specified herein):
(a)
Organization, Authority and
Significant Subsidiaries . The Company has been duly incorporated and is
validly existing and in good standing under the laws of its
jurisdiction of organization, with the necessary power and
authority to own its properties and conduct its business in all
material respects as currently conducted, and except as has not,
individually or in the aggregate, had and would not reasonably be
expected to have a Company Material Adverse Effect, has been duly
qualified as a foreign corporation for the transaction of business
and is in good standing under the laws of each other jurisdiction
in which it owns or leases properties or conducts any business so
as to require such qualification; each subsidiary of the Company
that is a “significant subsidiary” within the meaning
of Rule 1-02(w) of Regulation S-X under the Securities
Act of 1933 (the “ Securities Act ”) has been
duly organized and is validly existing in good standing under the
laws of its jurisdiction of organization. The Charter and bylaws of
the Company, copies of which have been provided to the Investor
prior to the Signing Date, are true, complete and correct copies of
such documents as in full force and effect as of the Signing
Date.
(b)
Capitalization
. The authorized capital stock of
the Company, and the outstanding capital stock of the Company
(including securities convertible into, or exercisable or
exchangeable for, capital stock of the Company) as of the most
recent fiscal month-end preceding the Signing Date (the “
Capitalization Date ”) is set forth on Schedule
B . The outstanding shares of capital stock of the Company have
been duly authorized and are validly issued and outstanding, fully
paid and nonassessable, and subject to no preemptive rights (and
were not issued in violation of any preemptive rights). Except as
provided in the Warrant, as of the Signing Date, the Company does
not have outstanding any securities or other obligations providing
the holder the right to acquire Common Stock that is not reserved
for issuance as
-5-
specified on Schedule B , and the Company
has not made any other commitment to authorize, issue or sell any
Common Stock. Since the Capitalization Date, the Company has not
issued any shares of Common Stock, other than (i) shares
issued upon the exercise of stock options or delivered under other
equity-based awards or other convertible securities or warrants
which were issued and outstanding on the Capitalization Date and
disclosed on Schedule B and (ii) shares disclosed on
Schedule B.
(c)
Preferred Shares
. The Preferred Shares have been
duly and validly authorized, and, when issued and delivered
pursuant to this Agreement, such Preferred Shares will be duly and
validly issued and fully paid and non-assessable, will not be
issued in violation of any preemptive rights, and will rank pari
passu with or senior to all other series or classes of
Preferred Stock, whether or not issued or outstanding, with respect
to the payment of dividends and the distribution of assets in the
event of any dissolution, liquidation or winding up of the
Company.
(d)
The Warrant and Warrant
Shares . The Warrant has
been duly authorized and, when executed and delivered as
contemplated hereby, will constitute a valid and legally binding
obligation of the Company enforceable against the Company in
accordance with its terms, except as the same may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting the enforcement of creditors’ rights
generally and general equitable principles, regardless of whether
such enforceability is considered in a proceeding at law or in
equity (“ Bankruptcy Exceptions ”). The shares
of Common Stock issuable upon exercise of the Warrant (the “
Warrant Shares ”) have been duly authorized and
reserved for issuance upon exercise of the Warrant and when so
issued in accordance with the terms of the Warrant will be validly
issued, fully paid and non-assessable, subject, if applicable, to
the approvals of its stockholders set forth on Schedule C
.
(e)
Authorization,
Enforceability .
(i)
The Company has the corporate power
and authority to execute and deliver this Agreement and the Warrant
and, subject, if applicable, to the approvals of its stockholders
set forth on Schedule C , to carry out its obligations
hereunder and thereunder (which includes the issuance of the
Preferred Shares, Warrant and Warrant Shares). The execution,
delivery and performance by the Company of this Agreement and the
Warrant and the consummation of the transactions contemplated
hereby and thereby have been duly authorized by all necessary
corporate action on the part of the Company and its stockholders,
and no further approval or authorization is required on the part of
the Company, subject, in each case, if applicable, to the approvals
of its stockholders set forth on Schedule C . This Agreement
is a valid and binding obligation of the Company enforceable
against the Company in accordance with its terms, subject to the
Bankruptcy Exceptions.
(ii)
The execution, delivery and
performance by the Company of this Agreement and the Warrant and
the consummation of the transactions contemplated hereby and
thereby and compliance by the Company with the provisions hereof
and
-6-
thereof, will not (A) violate,
conflict with, or result in a breach of any provision of, or
constitute a default (or an event which, with notice or lapse of
time or both, would constitute a default) under, or result in the
termination of, or accelerate the performance required by, or
result in a right of termination or acceleration of, or result in
the creation of, any lien, security interest, charge or encumbrance
upon any of the properties or assets of the Company or any Company
Subsidiary under any of the terms, conditions or provisions of
(i) subject, if applicable, to the approvals of the
Company’s stockholders set forth on Schedule C , its
organizational documents or (ii) any note, bond, mortgage,
indenture, deed of trust, license, lease, agreement or other
instrument or obligation to which the Company or any Company
Subsidiary is a party or by which it or any Company Subsidiary may
be bound, or to which the Company or any Company Subsidiary or any
of the properties or assets of the Company or any Company
Subsidiary may be subject, or (B) subject to compliance with
the statutes and regulations referred to in the next paragraph,
violate any statute, rule or regulation or any judgment,
ruling, order, writ, injunction or decree applicable to the Company
or any Company Subsidiary or any of their respective properties or
assets except, in the case of clauses (A)(ii) and (B), for
those occurrences that, individually or in the aggregate, have not
had and would not reasonably be expected to have a Company Material
Adverse Effect.
(iii)
Other than the filing of the
Certificate of Designations with the Secretary of State of its
jurisdiction of organization or other applicable Governmental
Entity, any current report on Form 8-K required to be filed
with the SEC, such filings and approvals as are required to be made
or obtained under any state “blue sky” laws, the filing
of any proxy statement contemplated by Section 3.1 and such as
have been made or obtained, no notice to, filing with, exemption or
review by, or authorization, consent or approval of, any
Governmental Entity is required to be made or obtained by the
Company in connection with the consummation by the Company of the
Purchase except for any such notices, filings, exemptions, reviews,
authorizations, consents and approvals the failure of which to make
or obtain would not, individually or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect.
(f)
Anti-takeover Provisions and
Rights Plan . The Board
of Directors of the Company (the “ Board of Directors
”) has taken all necessary action to ensure that the
transactions contemplated by this Agreement and the Warrant and the
consummation of the transactions contemplated hereby and thereby,
including the exercise of the Warrant in accordance with its terms,
will be exempt from any anti-takeover or similar provisions of the
Company’s Charter and bylaws, and any other provisions of any
applicable “moratorium”, “control share”,
“fair price”, “interested stockholder” or
other anti-takeover laws and regulations of any jurisdiction. The
Company has taken all actions necessary to render any
stockholders’ rights plan of the Company inapplicable to this
Agreement and the Warrant and the consummation of the transactions
contemplated hereby and thereby, including the exercise of the
Warrant by the Investor in accordance with its terms.
(g)
No Company Material Adverse
Effect . Since the last
day of the last completed fiscal period for which the Company has
filed a Quarterly Report on Form 10-Q or an Annual
-7-
Report on Form 10-K with the SEC prior to
the Signing Date, no fact, circumstance, event, change, occurrence,
condition or development has occurred that, individually or in the
aggregate, has had or would reasonably be expected to have a
Company Material Adverse Effect.
(h)
Company Financial
Statements . Each of the
consolidated financial statements of the Company and its
consolidated subsidiaries (collectively the “ Company
Financial Statements ”) included or incorporated by
reference in the Company Reports filed with the SEC since
December 31, 2006, present fairly in all material respects the
consolidated financial position of the Company and its consolidated
subsidiaries as of the dates indicated therein (or if amended prior
to the Signing Date, as of the date of such amendment) and the
consolidated results of their operations for the periods specified
therein; and except as stated therein, such financial statements
(A) were prepared in conformity with GAAP applied on a
consistent basis (except as may be noted therein), (B) have
been prepared from, and are in accordance with, the books and
records of the Company and the Company Subsidiaries and
(C) complied as to form, as of their respective dates of
filing with the SEC, in all material respects with the applicable
accounting requirements and with the published rules and
regulations of the SEC with respect thereto.
(i)
Reports .
(i)
Since December 31, 2006, the
Company and each subsidiary of the Company (each a “
Company Subsidiary ” and, collectively, the “
Company Subsidiaries ”) has timely filed all reports,
registrations, documents, filings, statements and submissions,
together with any amendments thereto, that it was required to file
with any Governmental Entity (the foregoing, collectively, the
“ Company Reports ”) and has paid all fees and
assessments due and payable in connection therewith, except, in
each case, as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect.
As of their respective dates of filing, the Company Reports
complied in all material respects with all statutes and applicable
rules and regulations of the applicable Governmental Entities.
In the case of each such Company Report filed with or furnished to
the SEC, such Company Report (A) did not, as of its date or if
amended prior to the Signing Date, as of the date of such
amendment, contain an untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements
made therein, in light of the circumstances under which they were
made, not misleading, and (B) complied as to form in all
material respects with the applicable requirements of the
Securities Act and the Exchange Act. With respect to all other
Company Reports, the Company Reports were complete and accurate in
all material respects as of their respective dates. No executive
officer of the Company or any Company Subsidiary has failed in any
respect to make the certifications required of him or her under
Section 302 or 906 of the Sarbanes-Oxley Act of
2002.
(ii)
The records, systems, controls, data
and information of the Company and the Company Subsidiaries are
recorded, stored, maintained and operated under means (including
any electronic, mechanical or photographic process, whether
computerized or not) that are under the exclusive ownership and
direct control of the Company or the
-8-
Company Subsidiaries or their
accountants (including all means of access thereto and therefrom),
except for any non-exclusive ownership and non-direct control that
would not reasonably be expected to have a material adverse effect
on the system of internal accounting controls described below in
this Section 2.2(i)(ii). The Company (A) has implemented
and maintains disclosure controls and procedures (as defined in
Rule 13a-15(e) of the Exchange Act) to ensure that
material information relating to the Company, including the
consolidated Company Subsidiaries, is made known to the chief
executive officer and the chief financial officer of the Company by
others within those entities, and (B) has disclosed, based on its
most recent evaluation prior to the Signing Date, to the
Company’s outside auditors and the audit committee of the
Board of Directors (x) any significant deficiencies and
material weaknesses in the design or operation of internal controls
over financial reporting (as defined in Rule 13a-15(f) of
the Exchange Act) that are reasonably likely to adversely affect
the Company’s ability to record, process, summarize and
report financial information and (y) any fraud, whether or not
material, that involves management or other employees who have a
significant role in the Company’s internal controls over
financial reporting.
(j)
No Undisclosed
Liabilities . Neither the
Company nor any of the Company Subsidiaries has any liabilities or
obligations of any nature (absolute, accrued, contingent or
otherwise) which are not properly reflected or reserved against in
the Company Financial Statements to the extent required to be so
reflected or reserved against in accordance with GAAP, except for
(A) liabilities that have arisen since the last fiscal year
end in the ordinary and usual course of business and consistent
with past practice and (B) liabilities that, individually or
in the aggregate, have not had and would not reasonably be expected
to have a Company Material Adverse Effect.
(k)
Offering of Securities
. Neither the Company nor any person
acting on its behalf has taken any action (including any offering
of any securities of the Company under circumstances which would
require the integration of such offering with the offering of any
of the Purchased Securities under the Securities Act, and the
rules and regulations of the SEC promulgated thereunder),
which might subject the offering, issuance or sale of any of the
Purchased Securities to Investor pursuant to this Agreement to the
registration requirements of the Securities Act.
(l)
Litigation and Other
Proceedings . Except
(i) as set forth on Schedule D or (ii) as would
not, individually or in the aggregate, reasonably be expected to
have a Company Material Adverse Effect, there is no
(A) pending or, to the knowledge of the Company, threatened,
claim, action, suit, investigation or proceeding, against the
Company or any Company Subsidiary or to which any of their assets
are subject nor is the Company or any Company Subsidiary subject to
any order, judgment or decree or (B) unresolved violation,
criticism or exception by any Governmental Entity with respect to
any report or relating to any examinations or inspections of the
Company or any Company Subsidiaries.
(m)
Compliance with Laws
. Except as would not, individually
or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect, the Company and the
-9-
Company Subsidiaries have all permits, licenses,
franchises, authorizations, orders and approvals of, and have made
all filings, applications and registrations with, Governmental
Entities that are required in order to permit them to own or lease
their properties and assets and to carry on their business as
presently conducted and that are material to the business of the
Company or such Company Subsidiary. Except as set forth on
Schedule E , the Company and the Company Subsidiaries have
complied in all respects and are not in default or violation of,
and none of them is, to the knowledge of the Company, under
investigation with respect to or, to the knowledge of the Company,
have been threatened to be charged with or given notice of any
violation of, any applicable domestic (federal, state or local) or
foreign law, statute, ordinance, license, rule, regulation, policy
or guideline, order, demand, writ, injunction, decree or judgment
of any Governmental Entity, other than such noncompliance, defaults
or violations that would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect.
Except for statutory or regulatory restrictions of general
application or as set forth on Schedule E , no Governmental
Entity has placed any restriction on the business or properties of
the Company or any Company Subsidiary that would, individually or
in the aggregate, reasonably be expected to have a Company Material
Adverse Effect.
(n)
Employee Benefit
Matters . Except as would
not reasonably be expected to have, either individually or in the
aggregate, a Company Material Adverse Effect: (A) each
“employee benefit plan” (within the meaning of
Section 3(3) of the Employee Retirement Income Security
Act of 1974, as amended (“ ERISA ”)) providing
benefits to any current or former employee, officer or director of
the Company or any member of its “ Controlled Group
” (defined as any organization which is a member of a
controlled group of corporations within the meaning of
Section 414 of the Internal Revenue Code of 1986, as amended
(the “ Code ”)) that is sponsored, maintained or
contributed to by the Company or any member of its Controlled Group
and for which the Company or any member of its Controlled Group
would have any liability, whether actual or contingent (each, a
“ Plan ”) has been maintained in compliance with
its terms and with the requirements of all applicable statutes,
rules and regulations, including ERISA and the Code;
(B) with respect to each Plan subject to Title IV of ERISA
(including, for purposes of this clause (B), any plan subject to
Title IV of ERISA that the Company or any member of its Controlled
Group previously maintained or contributed to in the six years
prior to the Signing Date), (1) no “reportable
event” (within the meaning of Section 4043(c) of
ERISA), other than a reportable event for which the notice period
referred to in Section 4043(c) of ERISA has been waived,
has occurred in the three years prior to the Signing Date or is
reasonably expected to occur, (2) no “accumulated
funding deficiency” (within the meaning of Section 302
of ERISA or Section 412 of the Code), whether or not waived, has
occurred in the three years prior to the Signing Date or is
reasonably expected to occur, (3) the fair market value of the
assets under each Plan exceeds the present value of all benefits
accrued under such Plan (determined based on the assumptions used
to fund such Plan) and (4) neither the Company nor any member
of its Controlled Group has incurred in the six years prior to the
Signing Date, or reasonably expects to incur, any liability under
Title IV of ERISA (other than contributions to the Plan or premiums
to the PBGC in the ordinary course and without default) in respect
of a Plan (including any Plan that is a “multiemployer
plan”, within the meaning of Section 4001(c)(3) of
ERISA); and (C) each Plan that is intended to be qualified
under Section 401(a) of the Code has received a
favorable
-10-
determination letter from the Internal Revenue
Service with respect to its qualified status that has not been
revoked, or such a determination letter has been timely applied for
but not received by the Signing Date, and nothing has occurred,
whether by action or by failure to act, which could reasonably be
expected to cause the loss, revocation or denial of such qualified
status or favorable determination letter.
(o)
Taxes . Except as would not, individually or in the
aggregate, reasonably be expected to have a Company Material
Adverse Effect, (i) the Company and the Company Subsidiaries
have filed all federal, state, local and foreign income and
franchise Tax returns required to be filed through the Signing
Date, subject to permitted extensions, and have paid all Taxes due
thereon, and (ii) no Tax deficiency has been determined
adversely to the Company or any of the Company Subsidiaries, nor
does the Company have any knowledge of any Tax deficiencies.
“ Tax ” or “ Taxes ” means
any federal, state, local or foreign income, gross receipts,
property, sales, use, license, excise, franchise, employment,
payroll, withholding, alternative or add on minimum, ad valorem,
transfer or excise tax, or any other tax, custom, duty,
governmental fee or other like assessment or charge of any kind
whatsoever, together with any interest or penalty, imposed by any
Governmental Entity.
(p)
Properties and Leases
. Except as would not, individually
or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect, the Company and the Company Subsidiaries
have good and marketable title to all real properties and all other
properties and assets owned by them, in each case free from liens,
encumbrances, claims and defects that would affect the value
thereof or interfere with the use made or to be made thereof by
them. Except as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect,
the Company and the Company Subsidiaries hold all leased real or
personal property under valid and enforceable leases with no
exceptions that would interfere with the use made or to be made
thereof by them.
(q)
Environmental
Liability . Except as
would not, individually or in the aggregate, reasonably be expected
to have a Company Material Adverse Effect:
(i)
there is no legal, administrative,
or other proceeding, claim or action of any nature seeking to
impose, or that would reasonably be expected to result in the
imposition of, on the Company or any Company Subsidiary, any
liability relating to the release of hazardous substances as
defined under any local, state or federal environmental statute,
regulation or ordinance, including the Comprehensive Environmental
Response, Compensation and Liability Act of 1980, pending or, to
the Company’s knowledge, threatened against the Company or
any Company Subsidiary;
(ii)
to the Company’s knowledge,
there is no reasonable basis for any such proceeding, claim or
action; and
(iii)
neither the Company nor any Company
Subsidiary is subject to any agreement, order, judgment or decree
by or with any court, Governmental Entity or third party imposing
any such environmental liability.
-11-
(r)
Risk Management Instruments . Except as would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect, all derivative instruments,
including, swaps, caps, floors and option agreements, whether
entered into for the Company’s own account, or for the
account of one or more of the Company Subsidiaries or its or their
customers, were entered into (i) only in the ordinary course
of business, (ii) in accordance with prudent practices and in
all material respects with all applicable laws, rules, regulations
and regulatory policies and (iii) with counterparties believed
to be financially responsible at the time; and each of such
instruments constitutes the valid and legally binding obligation of
the Company or one of the Company Subsidiaries, enforceable in
accordance with its terms, except as may be limited by the
Bankruptcy Exceptions. Neither the Company or the Company
Subsidiaries, nor, to the knowledge of the Company, any other party
thereto, is in breach of any of its obligations under any such
agreement or arrangement other than such breaches that would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect.
(s)
Agreements with Regulatory Agencies . Except as set forth on
Schedule F, neither the Company nor any Company Subsidiary
is subject to any material cease-and-desist or other similar order
or enforcement action issued by, or is a party to any material
written agreement, consent agreement or memorandum of understanding
with, or is a party to any commitment letter or similar undertaking
to, or is subject to any capital directive by, or since
December 31, 2006, has adopted any board resolutions at the
request of, any Governmental Entity (other than the Appropriate
Federal Banking Agencies with jurisdiction over the Company and the
Company Subsidiaries) that currently restricts in any material
respect the conduct of its business or that in any material manner
relates to its capital adequacy, its liquidity and funding policies
and practices, its ability to pay dividends, its credit, risk
management or compliance policies or procedures, its internal
controls, its management or its operations or business (each item
in this sentence, a “ Regulatory Agreement ”),
nor has the Company or any Company Subsidiary been advised since
December 31, 2006 by any such Governmental Entity that it is
considering issuing, initiating, ordering, or requesting any such
Regulatory Agreement. The Company and each Company Subsidiary are
in compliance in all material respects with each Regulatory
Agreement to which it is party or subject, and neither the Company
nor any Company Subsidiary has received any notice from any
Governmental Entity indicating that either the Company or any
Company Subsidiary is not in compliance in all material respects
with any such Regulatory Agreement. “ Appropriate Federal
Banking Agency ” means the “appropriate Federal
banking agency” with respect to the Company or such Company
Subsidiaries, as applicable, as defined in
Section 3(q) of the Federal Deposit Insurance Act (12
U.S.C. Section 1813(q)).
(t)
Insurance . The Company and the Company Subsidiaries are
insured with reputable insurers against such risks and in such
amounts as the management of the Company reasonably has determined
to be prudent and consistent with industry practice. The Company
and the Company Subsidiaries are in material compliance with their
insurance policies and are not in default under any of the material
terms thereof, each such policy is outstanding and in full force
and effect, all premiums and other payments due under any material
policy have been paid, and all claims thereunder have been filed in
due and timely fashion, except, in each case, as would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect.
-12-
(u)
Intellectual Property . Except as would not, individually or
in the aggregate, reasonably be expected to have a Company Material
Adverse Effect, (i) the Company and each Company Subsidiary
owns or otherwise has the right to use, all intellectual property
rights, including all trademarks, trade dress, trade names, service
marks, domain names, patents, inventions, trade secrets, know-how,
works of authorship and copyrights therein, that are used in the
conduct of their existing businesses and all rights relating to the
plans, design and specifications of any of its branch facilities
(“ Proprietary Rights ”) free and clear of all
liens and any claims of ownership by current or former employees,
contractors, designers or others and (ii) neither the Company
nor any of the Company Subsidiaries is materially infringing,
diluting, misappropriating or violating, nor has the Company or any
or the Company Subsidiaries received any written (or, to the
knowledge of the Company, oral) communications alleging that any of
them has materially infringed, diluted, misappropriated or
violated, any of the Proprietary Rights owned by any other person.
Except as would not, individually or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect, to the
Company’s knowledge, no other person is infringing, diluting,
misappropriating or violating, nor has the Company or any or the
Company Subsidiaries sent any written communications since
January 1, 2006 alleging that any person has infringed,
diluted, misappropriated or violated, any of the Proprietary Rights
owned by the Company and the Company Subsidiaries.
(v)
Brokers and Finders . No broker, finder or investment banker
is entitled to any financial advisory, brokerage, finder’s or
other fee or commission in connection with this Agreement or the
Warrant or the transactions contemplated hereby or thereby based
upon arrangements made by or on behalf of the Company or any
Company Subsidiary for which the Investor could have any
liability.
Article III
Covenants
3.1
Commercially Reasonable Efforts .
(a)
Subject to the terms and conditions of this Agreement, each of the
parties will use its commercially reasonable efforts in good faith
to take, or cause to be taken, all actions, and to do, or cause to
be done, all things necessary, proper or desirable, or advisable
under applicable laws, so as to permit consummation of the Purchase
as promptly as practicable and otherwise to enable consummation of
the transactions contemplated hereby and shall use commercially
reasonable efforts to cooperate with the other party to that
end.
(b)
If the Company is required to obtain any stockholder approvals set
forth on Schedule C, then the Company shall comply with this
Section 3.1(b) and Section 3.1(c). The Company shall
call a special meeting of its stockholders, as promptly as
practicable following the Closing, to vote on proposals
(collectively, the “ Stockholder Proposals ”) to
(i) approve the exercise of the Warrant for Common Stock for
purposes of the rules of the national security exchange on
which the Common Stock is listed and/or (ii) amend the
Company’s Charter to increase the number of authorized shares
of Common Stock to at least such number as shall be sufficient to
permit the full exercise of the Warrant for Common Stock and comply
with the
-13-
other provisions of this
Section 3.1(b) and Section 3.1(c). The Board of
Directors shall recommend to the Company’s stockholders that
such stockholders vote in favor of the Stockholder Proposals. In
connection with such meeting, the Company shall prepare (and the
Investor will reasonably cooperate with the Company to prepare) and
file with the SEC as promptly as practicable (but in no event more
than ten business days after the Closing) a preliminary proxy
statement, shall use its reasonable best efforts to respond to any
comments of the SEC or its staff thereon and to cause a definitive
proxy statement related to such stockholders’ meeting to be
mailed to the Company’s stockholders not more than five
business days after clearance thereof by the SEC, and shall use its
reasonable best efforts to solicit proxies for such stockholder
approval of the Stockholder Proposals. The Company shall notify the
Investor promptly of the receipt of any comments from the SEC or
its staff with respect to the proxy statement and of any request by
the SEC or its staff for amendments or supplements to such proxy
statement or for additional information and will supply the
Investor with copies of all correspondence between the Company or
any of its representatives, on the one hand, and the SEC or its
staff, on the other hand, with respect to such proxy statement. If
at any time prior to such stockholders’ meeting there shall
occur any event that is required to be set forth in an amendment or
supplement to the proxy statement, the Company shall as promptly as
practicable prepare and mail to its stockholders such an amendment
or supplement. Each of the Investor and the Company agrees promptly
to correct any information provided by it or on its behalf for use
in the proxy statement if and to the extent that such information
shall have become false or misleading in any material respect, and
the Company shall as promptly as practicable prepare and mail to
its stockholders an amendment or supplement to correct such
information to the extent required by applicable laws and
regulations. The Company shall consult with the Investor prior to
filing any proxy statement, or any amendment or supplement thereto,
and provide the Investor with a reasonable opportunity to comment
thereon. In the event that the approval of any of the Stockholder
Proposals is not obtained at such special stockholders meeting, the
Company shall include a proposal to approve (and the Board of
Directors shall recommend approval of) each such proposal at a
meeting of its stockholders no less than once in each subsequent
six-month period beginning on January 1, 2009 until all such
approvals are obtained or made.
(c)
None of the information supplied by the Company or any of the
Company Subsidiaries for inclusion in any proxy statement in
connection with any such stockholders meeting of the Company will,
at the date it is filed with the SEC, when first mailed to the
Company’s stockholders and at the time of any stockholders
meeting, and at the time of any amendment or supplement thereof,
contain any untrue statement of a material fact or omit to state
any material fact necessary in order to make the statements
therein, in light of the circumstances under which they are made,
not misleading.
3.2
Expenses. Unless otherwise provided in this Agreement or the
Warrant, each of the parties hereto will bear and pay all costs and
expenses incurred by it or on its behalf in connection with the
transactions contemplated under this Agreement and the Warrant,
including fees and expenses of its own financial or other
consultants, investment bankers, accountants and
counsel.
3.3
Sufficiency of Authorized Common Stock; Exchange Listing
.
-14-
(a)
During the period from the Closing Date (or, if the approval of the
Stockholder Proposals is required, the date of such approval) until
the date on which the Warrant has been fully exercised, the Company
shall at all times have reserved for issuance, free of preemptive
or similar rights, a sufficient number of authorized and unissued
Warrant Shares to effectuate such exercise. Nothing in this
Section 3.3 shall preclude the Company from satisfying its
obligations in respect of the exercise of the Warrant by delivery
of shares of Common Stock which are held in the treasury of the
Company. As soon as reasonably practicable following the Closing,
the Company shall, at its expense, cause the Warrant Shares to be
listed on the same national securities exchange on which the Common
Stock is listed, subject to official notice of issuance, and shall
maintain such listing for so long as any Common Stock is listed on
such exchange.
(b)
If requested by the Investor, the Company shall promptly use its
reasonable best efforts to cause the Preferred Shares to be
approved for listing on a national securities exchange as promptly
as practicable following such request.
3.4
Certain Notifications Until Closing . From the Signing Date
until the Closing, the Company shall promptly notify the Investor
of (i) any fact, event or circumstance of which it is aware
and which would reasonably be expected to cause any representation
or warranty of the Company contained in this Agreement to be untrue
or inaccurate in any material respect or to cause any covenant or
agreement of the Company contained in this Agreement not to be
complied with or satisfied in any material respect and
(ii) except as Previously Disclosed, any fact, circumstance,
event, change, occurrence, condition or development of which the
Company is aware and which, individually or in the aggregate, has
had or would reasonably be expected to have a Company Material
Adverse Effect; provided , however , that delivery of
any notice pursuant to this Section 3.4 shall not limit or
affect any rights of or remedies available to the Investor;
provided , further , that a failure to comply with
this Section 3.4 shall not constitute a breach of this
Agreement or the failure of any condition set forth in
Section 1.2 to be satisfied unless the underlying Company
Material Adverse Effect or material breach would independently
result in the failure of a condition set forth in Section 1.2
to be satisfied.
3.5
Access, Information and Confidentiality .
(a)
From the Signing Date until the date when the Investor holds an
amount of Preferred Shares having an aggregate liquidation value of
less than 10% of the Purchase Price, the Company will permit the
Investor and its agents, consultants, contractors and advisors
(x) acting through the Appropriate Federal Banking Agency, to
examine the corporate books and make copies thereof and to discuss
the affairs, finances and accounts of the Company and the Company
Subsidiaries with the principal officers of the Company, all upon
reasonable notice and at such reasonable times and as often as the
Investor may reasonably request and (y) to review any
information material to the Investor’s investment in the
Company provided by the Company to its Appropriate Federal Banking
Agency. Any investigation pursuant to this Section 3.5 shall
be conducted during normal business hours and in such manner as not
to interfere unreasonably with the conduct of the business of the
Company, and nothing herein shall require the Company or any
Company Subsidiary to disclose any information to the Investor to
the extent (i) prohibited by applicable law or regulation, or
(ii) that such disclosure would reasonably be
-15-
expected to cause a violation of any agreement
to which the Company or any Company Subsidiary is a party or would
cause a risk of a loss of privilege to the Company or any Company
Subsidiary ( provided that the Company shall use
commercially reasonable efforts to make appropriate substitute
disclosure arrangements under circumstances where the restrictions
in this clause (ii) apply).
(b)
The Investor will use reasonable best efforts to hold, and will use
reasonable best efforts to cause its agents, consultants,
contractors and advisors to hold, in confidence all non-public
records, books, contracts, instruments, computer data and other
data and information (collectively, “ Information
”) concerning the Company furnished or made available to it
by the Company or its representatives pursuant to this Agreement
(except to the extent that such information can be shown to have
been (i) previously known by such party on a non-confidential
basis, (ii) in the public domain through no fault of such
party or (iii) later lawfully acquired from other sources by
the party to which it was furnished (and without violation of any
other confidentiality obligation)); provided that nothing
herein shall prevent the Investor from disclosing any Information
to the extent required by applicable laws or regulations or by any
subpoena or similar legal process.
Article IV
Additional Agreements
4.1
Purchase for Investment. The Investor acknowledges that the
Purchased Securities and the Warrant Shares have not been
registered under the Securities Act or under any state securities
laws. The Investor (a) is acquiring the Purchased Securities
pursuant to an exemption from registration under the Securities Act
solely for investment with no present intention to distribute them
to any person in violation of the Securities Act or any applicable
U.S. state securities laws, (b) will not sell or otherwise
dispose of any of the Purchased Securities or the Warrant Shares,
except in compliance with the registration requirements or
exemption provisions of the Securities Act and any applicable U.S.
state securities laws, and (c) has such knowledge and
experience in financial and business matters and in investments of
this type that it is capable of evaluating the merits and risks of
the Purchase and of making an informed investment
decision.
4.2
Legends.
(a)
The Investor agrees that all certificates or other instruments
representing the Warrant and the Warrant Shares will bear a legend
substantially to the following effect:
“THE SECURITIES REPRESENTED BY
THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND
MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF EXCEPT
WHILE A REGISTRATION STATEMENT RELATING THERETO IS IN EFFECT UNDER
SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN
EXEMPTION FROM REGISTRATION UNDER SUCH ACT OR SUCH
LAWS.”
-16-
(b)
The Investor agrees that all certificates or other instruments
representing the Warrant will also bear a legend substantially to
the following effect:
“THIS INSTRUMENT IS ISSUED
SUBJECT TO THE RESTRICTIONS ON TRANSFER AND OTHER PROVISIONS OF A
SECURITIES PURCHASE AGREEMENT BETWEEN THE ISSUER OF THESE
SECURITIES AND THE INVESTOR REFERRED TO THEREIN, A COPY OF WHICH IS
ON FILE WITH THE ISSUER. THE SECURITIES REPRESENTED BY THIS
INSTRUMENT MAY NOT BE SOLD OR OTHERWISE TRANSFERRED EXCEPT IN
COMPLIANCE WITH SAID AGREEMENT. ANY SALE OR OTHER TRANSFER NOT IN
COMPLIANCE WITH SAID AGREEMENT WILL BE VOID.”
(c)
In addition, the Investor agrees that all certificates or other
instruments representing the Preferred Shares will bear a legend
substantially to the following effect:
“THE SECURITIES REPRESENTED BY
THIS INSTRUMENT ARE NOT SAVINGS ACCOUNTS, DEPOSITS OR OTHER
OBLIGATIONS OF A BANK AND ARE NOT INSURED BY THE FEDERAL DEPOSIT
INSURANCE CORPORATION OR ANY OTHER GOVERNMENTAL AGENCY.
THE SECURITIES REPRESENTED BY THIS
INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “SECURITIES ACT”), OR THE
SECURITIES LAWS OF ANY STATE AND MAY NOT BE TRANSFERRED, SOLD
OR OTHERWISE DISPOSED OF EXCEPT WHILE A REGISTRATION STATEMENT
RELATING THERETO IS IN EFFECT UNDER SUCH ACT AND APPLICABLE STATE
SECURITIES LAWS OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER
SUCH ACT OR SUCH LAWS. EACH PURCHASER OF THE SECURITIES REPRESENTED
BY THIS INSTRUMENT IS NOTIFIED THAT THE SELLER MAY BE RELYING
ON THE EXEMPTION FROM SECTION 5 OF THE SECURITIES ACT PROVIDED
BY RULE 144A THEREUNDER. ANY TRANSFEREE OF THE SECURITIES
REPRESENTED BY THIS INSTRUMENT BY ITS ACCEPTANCE HEREOF
(1) REPRESENTS THAT IT IS A “QUALIFIED INSTITUTIONAL
BUYER” (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT),
(2) AGREES THAT IT WILL NOT OFFER, SELL OR OTHERWISE TRANSFER
THE SECURITIES REPRESENTED BY THIS INSTRUMENT EXCEPT (A) PURSUANT
TO A REGISTRATION STATEMENT WHICH IS THEN EFFECTIVE UNDER THE
SECURITIES ACT, (B) FOR SO LONG AS THE SECURITIES REPRESENTED
BY THIS INSTRUMENT ARE ELIGIBLE FOR RESALE PURSUANT TO RULE 144A,
TO A PERSON IT REASONABLY BELIEVES IS A “QUALIFIED
INSTITUTIONAL BUYER” AS DEFINED IN RULE 144A UNDER THE
SECURITIES ACT THAT PURCHASES FOR ITS OWN ACCOUNT OR FOR THE
ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER TO WHOM NOTICE IS GIVEN
THAT THE TRANSFER IS BEING MADE IN RELIANCE ON RULE 144A,
(C) TO THE ISSUER OR (D) PURSUANT TO ANY OTHER AVAILABLE
EXEMPTION FROM THE REGISTRATION
-17-
REQUIREMENTS OF THE SECURITIES ACT
AND (3) AGREES THAT IT WILL GIVE TO EACH PERSON TO WHOM THE
SECURITIES REPRESENTED BY THIS INSTRUMENT ARE TRANSFERRED A NOTICE
SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND.”
(d)
In the event that any Purchased Securities or Warrant Shares
(i) become registered under the Securities Act or
(ii) are eligible to be transferred without restriction in
accordance with Rule 144 or another exemption from
registration under the Securities Act (other than Rule 144A),
the Company shall issue new certificates or other instruments
representing such Purchased Securities or Warrant Shares, which
shall not contain the applicable legends in Sections
4.2(a) and (c) above; provided that the Investor
surrenders to the Company the previously issued certificates or
other instruments. Upon Transfer of all or a portion of the Warrant
in compliance with Section 4.4, the Company shall issue new
certificates or other instruments representing the Warrant, which
shall not contain the applicable legend in
Section 4.2(b) above; provided that the Investor
surrenders to the Company the previously issued certificates or
other instruments.
4.3
Certain Transactions . The Company will not merge or
consolidate with, or sell, transfer or lease all or substantially
all of its property or assets to, any other party unless the
successor, transferee or lessee party (or its ultimate parent
entity), as the case may be (if not the Company), expressly assumes
the due and punctual performance and observance of each and every
covenant, agreement and condition of this Agreement to be performed
and observed by the Company.
4.4
Transfer of Purchased Securities and Warrant Shares;
Restrictions on Exercise of the Warrant . Subject to compliance
with applicable securities laws, the Investor shall be permitted to
transfer, sell, assign or otherwise dispose of (“
Transfer ”) all or a portion of the Purchased
Securities or Warrant Shares at any time, and the Company shall
take all steps as may be reasonably requested by the Investor to
facilitate the Transfer of the Purchased Securities and the Warrant
Shares; provided that the Investor shall not Transfer a
portion or portions of the Warrant with respect to, and/or exercise
the Warrant for, more than one-half of the Initial Warrant Shares
(as such number may be adjusted from time to time pursuant to
Section 13 thereof) in the aggregate until the earlier of
(a) the date on which the Company (or any successor by
Business Combination) has received aggregate gross proceeds of not
less than the Purchase Price (and the purchase price paid by the
Investor to any such successor for securities of such successor
purchased under the CPP) from one or more Qualified Equity
Offerings (including Qualified Equity Offerings of such successor)
and (b) December 31, 2009. “ Qualified Equity
Offering ” means the sale and issuance for cash by the
Company to persons other than the Company or any of the Company
Subsidiaries after the Closing Date of shares of perpetual
Preferred Stock, Common Stock or any combination of such stock,
that, in each case, qualify as and may be included in Tier 1
capital of the Company at the time of issuance under the applicable
risk-based capital guidelines of the Company’s Appropriate
Federal Banking Agency (other than any such sales and issuances
made pursuant to agreements or arrangements entered into, or
pursuant to financing plans which were publicly announced, on or
prior to October 13,
-18-
2008). “ Business Combination
” means a merger, consolidation, statutory share exchange or
similar transaction that requires the approval of the
Company’s stockholders.
4.5
Registration Rights.
(a)
Registration.
(i)
Subject to the terms and conditions of this Agreement, the Company
covenants and agrees that as promptly as practicable after the
Closing Date (and in any event no later than 30 days after the
Closing Date), the Company shall prepare and file with the SEC a
Shelf Registration Statement covering all Registrable Securities
(or otherwise designate an existing Shelf Registration Statement
filed with the SEC to cover the Registrable Securities), and, to
the extent the Shelf Registration Statement has not theretofore
been declared effective or is not automatically effective upon such
filing, the Company shall use reasonable best efforts to cause such
Shelf Registration Statement to be declared or become effective and
to keep such Shelf Registration Statement continuously effective
and in compliance with the Securities Act and usable for resale of
such Registrable Securities for a period from the date of its
initial effectiveness until such time as there are no Registrable
Securities remaining (including by refiling such Shelf Registration
Statement (or a new Shelf Registration Statement) if the initial
Shelf Registration Statement expires). So long as the Company is a
well-known seasoned issuer (as defined in Rule 405 under the
Securities Act) at the time of filing of the Shelf Registration
Statement with the SEC, such Shelf Registration Statement shall be
designated by the Company as an automatic Shelf Registration
Statement. Notwithstanding the foregoing, if on the Signing Date
the Company is not eligible to file a registration statement on
Form S-3, then the Company shall not be obligated to file a
Shelf Registration Statement unless and until requested to do so in
writing by the Investor.
(ii)
Any registration pursuant to Section 4.5(a)(i) shall be
effected by means of a shelf registration on an appropriate form
under Rule 415 under the Securities Act (a “ Shelf
Registration Statement ”). If the Investor or any other
Holder intends to distribute any Registrable Securities by means of
an underwritten offering it shall promptly so advise the Company
and the Company shall take all reasonable steps to facilitate such
distribution, including the actions required pursuant to
Section 4.5(c); provided that the Company shall not be
required to facilitate an underwritten offering of Registrable
Securities unless the expected gross proceeds from such offering
exceed (i) 2% of the initial aggregate liquidation preference
of the Preferred Shares if such initial aggregate liquidation
preference is less than $2 billion and (ii) $200 million if
the initial aggregate liquidation preference of the Preferred
Shares is equal to or greater than $2 billion. The lead
underwriters in any such distribution shall be selected by the
Holders of a majority of the Registrable Securities to be
distributed; provided that to the extent appropriate and
permitted under applicable law, such Holders shall consider the
qualifications of any broker-dealer Affiliate of the Company in
selecting the lead underwriters in any such
distribution.
-19-
(iii)
The Company shall not be required to
effect a registration (including a resale of Registrable Securities
from an effective Shelf Registration Statement) or an underwritten
offering pursuant to Section 4.5(a): (A) with respect to
securities that are not Registrable Securities; or (B) if the
Company has notified the Investor and all other Holders that in the
good faith judgment of the Board of Directors, it would be
materially detrimental to the Company or its securityholders for
such registration or underwritten offering to be effected at such
time, in which event the Company shall have the right to defer such
registration for a period of not more than 45 days after receipt of
the request of the Investor or any other Holder; provided
that such right to delay a registration or underwritten offering
shall be exercised by the Company (1) only if the Company has
generally exercised (or is concurrently exercising) similar
black-out rights against holders of similar securities that have
registration rights and (2) not more than three times in any
12-month period and not more than 90 days in the aggregate in any
12-month period.
(iv)
If during any period when an
effective Shelf Registration Statement is not available, the
Company proposes to register any of its equity securities, other
than a registration pursuant to Section 4.5(a)(i) or a
Special Registration, and the registration form to be filed may be
used for the registration or qualification for distribution of
Registrable Securities, the Company will give prompt written notice
to the Investor and all other Holders of its intention to effect
such a registration (but in no event less than ten days prior to
the anticipated filing date) and will include in such registration
all Registrable Securities with respect to which the Company has
received written requests for inclusion therein within ten business
days after the date of the Company’s notice (a “
Piggyback Registration ”). Any such person that has
made such a written request may withdraw its Registrable Securities
from such Piggyback Registration by giving written notice to the
Company and the managing underwriter, if any, on or before the
fifth business day prior to the planned effective date of such
Piggyback Registration. The Company may terminate or withdraw any
registration under this Section 4.5(a)(iv) prior to the
effectiveness of such registration, whether or not Investor or any
other Holders have elected to include Registrable Securities in
such registration.
(v)
If the registration referred to in
Section 4.5(a)(iv) is proposed to be underwritten, the
Company will so advise Investor and all other Holders as a part of
the written notice given pursuant to Section 4.5(a)(iv). In
such event, the right of Investor and all other Holders to
registration pursuant to Section 4.5(a) will be
conditioned upon such persons’ participation in such
underwriting and the inclusion of such person’s Registrable
Securities in the underwriting if such securities are of the same
class of securities as the securities to be offered in the
underwritten offering, and each such person will (together with the
Company and the other persons distributing their securities through
such underwriting) enter into an underwriting agreement in
customary form with the underwriter or underwriters selected for
such underwriting by the Company; provided that the Investor
(as opposed to other Holders) shall not be required to indemnify
any person in connection with any registration. If any
participating person disapproves of the terms of the underwriting,
such person may elect to withdraw therefrom by written
notice
-20-
to the Company, the managing
underwriters and the Investor (if the Investor is participating in
the underwriting).
(vi)
If either (x) the Company
grants “piggyback” registration rights to one or more
third parties to include their securities in an underwritten
offering under the Shelf Registration Statement pursuant to
Section 4.5(a)(ii) or (y) a Piggyback Registration
under Section 4.5(a)(iv) relates to an underwritten
offering on behalf of the Company, and in either case the managing
underwriters advise the Company that in their reasonable opinion
the number of securities requested to be included in such offering
exceeds the number which can be sold without adversely affecting
the marketability of such offering (including an adverse effect on
the per share offering price), the Company will include in such
offering only such number of securities that in the reasonable
opinion of such managing underwriters can be sold without adversely
affecting the marketability of the offering (including an adverse
effect on the per share offering price), which securities will be
so included in the following order of priority: (A) first, in
the case of a Piggyback Registration under Section 4.5(a)(iv),
the securities the Company proposes to sell, (B) then the
Registrable Securities of the Investor and all other Holders who
have requested inclusion of Registrable Securities pursuant to
Section 4.5(a)(ii) or Section 4.5(a)(iv), as
applicable, pro rata on the basis of the aggregate number of
such securities or shares owned by each such person and
(C) lastly, any other securities of the Company that have been
requested to be so included, subject to the terms of this
Agreement; provided, however, that if the Company has, prior
to the Signing Date, entered into an agreement with respect to its
securities that is inconsistent with the order of priority
contemplated hereby then it shall apply the order of priority in
such conflicting agreement to the extent that it would otherwise
result in a breach under such agreement.
(b)
Expenses of
Registration . All
Registration Expenses incurred in connection with any registration,
qualification or compliance hereunder shall be borne by the
Company. All Selling Expenses incurred in connection with any
registrations hereunder shall be borne by the holders of the
securities so registered pro rata on the basis of the
aggregate offering or sale price of the securities so
registered.
(c)
Obligations of the
Company . The Company
shall use its reasonable best efforts, for so long as there are
Registrable Securities outstanding, to take such actions as are
under its control to not become an ineligible issuer (as defined in
Rule 405 under the Securities Act) and to remain a well-known
seasoned issuer (as defined in Rule 405 under the Securities
Act) if it has such status on the Signing Date or becomes eligible
for such status in the future. In addition, whenever required to
effect the registration of any Registrable Securities or facilitate
the distribution of Registrable Securities pursuant to an effective
Shelf Registration Statement, the Company shall, as expeditiously
as reasonably practicable:
(i)
Prepare and file with the SEC a
prospectus supplement with respect to a proposed offering of
Registrable Securities pursuant to an effective registration
statement, subject to Section 4.5(d), keep such registration
statement effective and keep
-21-
such prospectus supplement current
until the securities described therein are no longer Registrable
Securities.
(ii)
Prepare and file with the SEC such
amendments and supplements to the applicable registration statement
and the prospectus or prospectus supplement used in connection with
such registration statement as may be necessary to comply with the
provisions of the Securities Act with respect to the disposition of
all securities covered by such registration statement.
(iii)
Furnish to the Holders and any
underwriters such number of copies of the applicable registration
statement and each such amendment and supplement thereto (including
in each case all exhibits) and of a prospectus, including a
preliminary prospectus, in conformity with the requirements of the
Securities Act, and such other documents as they may reasonably
request in order to facilitate the disposition of Registrable
Securities owned or to be distributed by them.
(iv)
Use its reasonable best efforts to
register and qualify the securities covered by such registration
statement under such other securities or Blue Sky laws of such
jurisdictions as shall be reasonably requested by the Holders or
any managing underwriter(s), to keep such registration or
qualification in effect for so long as such registration statement
remains in effect, and to take any other action which may be
reasonably necessary to enable such seller to consummate the
disposition in such jurisdictions of the securities owned by such
Holder; provided that the Company shall not be required in
connection therewith or as a condition thereto to qualify to do
business or to file a general consent to service of process in any
such states or jurisdictions.
(v)
Notify each Holder of Registrable
Securities at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening
of any event as a result of which the applicable prospectus, as
then in effect, includes an untrue statement of a material fact or
omits to state a material fact required to be stated therein or
necessary to make the statements therein not misleading in light of
the circumstances then existing.
(vi)
Give written notice to the
Holders:
(A)
when any registration statement
filed pursuant to Section 4.5(a) or any amendment thereto
has been filed with the SEC (except for any amendment effected by
the filing of a document with the SEC pursuant to the Exchange Act)
and when such registration statement or any post-effective
amendment thereto has become effective;
(B)
of any request by the SEC for
amendments or supplements to any registration statement or the
prospectus included therein or for additional
information;
-22-
(C)
of the issuance by the SEC of any
stop order suspending the effectiveness of any registration
statement or the initiation of any proceedings for that
purpose;
(D)
of the receipt by the Company or its
legal counsel of any notification with respect to the suspension of
the qualification of the Common Stock for sale in any jurisdiction
or the initiation or threatening of any proceeding for such
purpose;
(E)
of the happening of any event that
requires the Company to make changes in any effective registration
statement or the prospectus related to the registration statement
in order to make the statements therein not misleading (which
notice shall be accompanied by an instruction to suspend the use of
the prospectus until the requisite changes have been made);
and
(F)
if at any time the representations
and warranties of the Company contained in any underwriting
agreement contemplated by Section 4.5(c)(x) cease to be
true and correct.
(vii)
Use its reasonable best efforts to
prevent the issuance or obtain the withdrawal of any order
suspending the effectiveness of any registration statement referred
to in Section 4.5(c)(vi)(C) at the earliest practicable
time.
(viii)
Upon the occurrence of any event
contemplated by Section 4.5(c)(v) or 4.5(c)(vi)(E),
promptly prepare a post-effective amendment to such registration
statement or a supplement to the related prospectus or file any
other required document so that, as thereafter delivered to the
Holders and any underwriters, the prospectus will not contain an
untrue statement of a material fact or omit to state any material
fact necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading. If the
Company notifies the Holders in accordance with
Section 4.5(c)(vi)(E) to suspend the use of the
prospectus until the requisite changes to the prospectus have been
made, then the Holders and any underwriters shall suspend use of
such prospectus and use their reasonable best efforts to return to
the Company all copies of such prospectus (at the Company’s
expense) other than permanent file copies then in such
Holders’ or underwriters’ possession. The total number
of days that any such suspension may be in effect in any 12-month
period shall not exceed 90 days.
(ix)
Use reasonable best efforts to
procure the cooperation of the Company’s transfer agent in
settling any offering or sale of Registrable Securities, including
with respect to the transfer of physical stock certificates into
book-entry form in accordance with any procedures reasonably
requested by the Holders or any managing underwriter(s).
(x)
If an underwritten offering is
requested pursuant to Section 4.5(a)(ii), enter into an
underwriting agreement in customary form, scope and substance and
take all such
-23-
other actions reasonably requested
by the Holders of a majority of the Registrable Securities being
sold in connection therewith or by the managing underwriter(s), if
any, to expedite or facilitate the underwritten disposition of such
Registrable Securities, and in connection therewith in any
underwritten offering (including making members of management and
executives of the Company available to participate in “road
shows”, similar sales events and other marketing activities),
(A) make such representations and warranties to the Holders
that are selling stockholders and the managing underwriter(s), if
any, with respect to the business of the Company and its
subsidiaries, and the Shelf Registration Statement, prospectus and
documents, if any, incorporated or deemed to be incorporated by
reference therein, in each case, in customary form, substance and
scope, and, if true, confirm the same if and when requested,
(B) use its reasonable best efforts to furnish the
underwriters with opinions of counsel to the Company, addressed to
the managing underwriter(s), if any, covering the matters
customarily covered in such opinions requested in underwritten
offerings, (C) use its reasonable best efforts to obtain
“cold comfort” letters from the independent certified
public accountants of the Company (and, if necessary, any other
independent certified public accountants of any business acquired
by the Company for which financial statements and financial data
are included in the Shelf Registration Statement) who have
certified the financial statements included in such Shelf
Registration Statement, addressed to each of the managing
underwriter(s), if any, such letters to be in customary form and
covering matters of the type customarily covered in “cold
comfort” letters, (D) if an underwriting agreement is
entered into, the same shall contain indemnification provisions and
procedures customary in underwritten offerings (provided that the
Investor shall not be obligated to provide any indemnity), and
(E) deliver such documents and certificates as may be
reasonably requested by the Holders of a majority of the
Registrable Securities being sold in connection therewith, their
counsel and the managing underwriter(s), if any, to evidence the
continued validity of the representations and warranties made
pursuant to clause (i) above and to evidence compliance with any
customary conditions contained in the underwriting agreement or
other agreement entered into by the Company.
(xi)
Make available for inspection by a
representative of Holders that are selling stockholders, the
managing underwriter(s), if any, and any attorneys or accountants
retained by such Holders or managing underwriter(s), at the offices
where normally kept, during reasonable business hours, financial
and other records, pertinent corporate documents and properties of
the Company, and cause the officers, directors and employees of the
Company to supply all information in each case reasonably requested
(and of the type customarily provided in connection with due
diligence conducted in connection with a registered public offering
of securities) by any such representative, managing underwriter(s),
attorney or accountant in connection with such Shelf Registration
Statement.
(xii)
Use reasonable best efforts to cause
all such Registrable Securities to be listed on each national
securities exchange on which similar securities issued by the
Company are then listed or, if no similar securities issued by the
Company are then listed on any national securities exchange, use
its reasonable best efforts to cause all such
-24-
Registrable Securities to be listed
on such securities exchange as the Investor may
designate.
(xiii)
If requested by Holders of a
majority of the Registrable Securities being registered and/or sold
in connection therewith, or the managing underwriter(s), if any,
promptly include in a prospectus supplement or amendment such
information as the Holders of a majority of the Registrable
Securities being registered and/or sold in connection therewith or
managing underwriter(s), if any, may reasonably request in order
to